Citations

Showing 10 of 108081 citations.

Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure
Rafique, Zubaid , Weir, Matthew R. , Lafayette, Richard , Butler, Javed , Farnum, Carolyn, Onuigbo, Macaulay , Pitt, Bertram , Lopes, Maria Carolina Barbosa Teixeira , Peacock, William Frank

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | May 9, 2017 | Volume: 23 | Issue: 4-a Suppl | Pages: S10-S19

10.18553/jmcp.2017.23.4-a.s10 | PMID 28485203 Get It

Management of macroglobulinaemia
Gertz, Morie A.

Mayo Clinic

British Journal of Haematology | May 9, 2017 | Volume: 177 | Issue: 5 | Pages: 669-671

10.1111/bjh.14742 | PMID 28485069 Get It

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Kumar, Shaji , Moreau, Philippe , Mateos, María‐Victoria , Shustik, Chaim, Masszi, Tamás , Spencer, Andrew , Hájek, Roman , Romeril, Kenneth, Avivi, Irit , Liberati, Anna Marina , Berg, Deborah, Lin, Jianchang , Gupta, Neeraj , Esseltine, Dixie‐Lee, Richardson, Paul G. , Einsele, Hermann , Gupta, Neeraj , Hari, Parameswaran , Ludwig, Heinz , Minnema, Monique C , Lonial, Sagar , Richardson, Paul Gerard Guy , Hajek, Roman , Moreau, Philippe , Masszi, Tamas

Mayo Clinic

British Journal of Haematology | May 9, 2017 | Volume: 178 | Issue: 4 | Pages: 571-582

10.1111/bjh.14733 | PMID 28485007 Get It

SummaryThe oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double‐blind, placebo‐controlled Phase III TOURMALINE‐MM1 study of ixazomib‐Rd (IRd) versus placebo‐Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression‐free survival versus placebo‐Rd (median: 20·6 vs. 14·7 months; hazard ratio 0·74). Common toxicities observed more commonly with IRd versus placebo‐Rd were thrombocytopenia, nausea, vomiting, diarrhoea, constipation, rash, peripheral neuropathy, peripheral oedema and back pain; these were generally grade 1/2 in severity except for thrombocytopenia (19% vs. 9% grade 3/4), which appeared manageable and reversible, with no differences between arms in significant bleeding or dose discontinuations. No cumulative toxicities were observed, indicating the potential feasibility of long‐term IRd treatment. Safety data from TOURMALINE‐MM1 are reviewed and guidance for managing clinically relevant adverse events associated with IRd is provided. Most toxicities were manageable with supportive care and dose delays or reductions as needed. Clinicians should be aware of and understand these potential side effects to optimise and prolong patient benefit.
Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US
Heit, John A. , Crusan, Daniel J. , Ashrani, Aneel A. , Petterson, Tanya M. , Bailey, Kent R.

Mayo Clinic

Blood | May 9, 2017 | Volume: 130 | Issue: 2 | Pages: 109-114

10.1182/blood-2016-12-758995 | PMID 28483763 Get It

Key PointsApproximately 500 000 US VTE events occur annually; approximately one-half are related to current or recent hospitalization. VTE attack rates (2005-2010) did not change despite near-universal in-hospital VTE prophylaxis, possibly due to short prophylaxis duration.
Development of High-Grade Daptomycin Resistance in a Patient Being Treated for Corynebacterium striatum Infection
AJMAL, SAIRA, Saleh, Omar Abu , Beam, Elena

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 9, 2017 | Volume: 61 | Issue: 7 | Pages: No page available

10.1128/aac.00705-17 | PMID 28483949 Get It

Intramyocellular Ceramides: Subcellular Concentrations and Fractional De Novo Synthesis in Postabsorptive Humans
Chung, Jin Ook , Koutsari, Christina , Błachnio‐Zabielska, Agnieszka , Hames, Kazanna C. , Jensen, Michael D.

Mayo Clinic

Diabetes | May 9, 2017 | Volume: 66 | Issue: 8 | Pages: 2082-2091

10.2337/db17-0082 | PMID 28483801 Get It

We investigated the relationship between insulin resistance markers and subsarcolemmal (SS) and intramyofibrillar (IMF) ceramide concentrations, as well as the contribution of plasma palmitate (6.5-h infusion of [U-13C]palmitate) to intramyocellular ceramides. Seventy-six postabsorptive men and women had muscle biopsies 1.5, 6.5, and 24 h after starting the tracer infusion. Concentrations and enrichment of muscle ceramides were measured by liquid chromatography-tandem mass spectrometry. We found that HOMA of insulin resistance, plasma insulin, and triglyceride concentrations were positively correlated with SS C16:0 and C18:1 ceramide, but not SS C14:0-Cer, C20:0-Cer, C24:0-Cer, and C24:1-Cer concentrations; IMF ceramide concentrations were not correlated with any metabolic parameters. The fractional contribution of plasma palmitate to 16:0 ceramide was greater in SS than IMF (SS, 18.2% vs. IMF, 8.7%; P = 0.0006). Plasma insulin concentrations correlated positively with the fractional contribution of plasma palmitate to SS 16:0 ceramide. The fractional contribution of plasma palmitate to intramyocellular SS 16:0 ceramide was positively correlated with SS C16:0 ceramide concentrations (γ = 0.435; P = 0.002). We conclude that skeletal muscle SS ceramides, especially C16 to C18 chain lengths and the de novo synthesis of intramyocellular ceramide from plasma palmitate are associated with markers of insulin resistance.
Clinical Reasoning: A 45-year-old man with weakness and myalgia after orthopedic surgery
Campo, Rocio Vazquez Do , Siegel, Jason , Dimberg, Elliot L., Vazquez do Campo, Rocio, Dimberg, Elliot, Goldstein, Eric , Vazquez Do Campo, Rocio

Mayo Clinic

Neurology | May 8, 2017 | Volume: 88 | Issue: 19 | Pages: No page available

10.1212/wnl.0000000000003914 | PMID 28483995 Get It

Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer
Braggio, Esteban , Cesarman-Maus, Gabriela, Fonseca, Rafaël , Cesarman‐Maus, Gabriela , Braggio, Esteban

Mayo Clinic

Journal of Clinical Oncology | May 8, 2017 | Volume: 35 | Issue: 19 | Pages: 2217-2218

10.1200/jco.2017.72.5341 | PMID 28481704 Get It

Abstract B45: Endometrial cancer microbiome signature and its implications for carcinogenesis
Hokenstad, Alexis, Distad, Tammy, Cheek, Heidi, Keeney, Gary L., Creedon, Douglas J., Nelson, Heidi D , Mariani, Andrea , Walther-António, Marina , Chen, Jun , Multinu, Francesco , Mariani, Andrea , Chia, Nicholas

Mayo Clinic

Clinical Cancer Research | May 8, 2017 | Volume: 23 | Issue: 1_Supplement | Pages: B45-B45

10.1158/1557-3265.pmccavuln16-b45 Get It

Abstract Endometrial cancer studies have led to a number of well-defined but mechanistically unconnected genetic and environmental risk factors. One of the emerging modulators between environmental triggers and genetic expression is the microbiome. Because of the inflammatory display in endometrial cancer, we set out to inquire about the composition of the uterine microbiome and its putative role in endometrial cancer. We undertook a pilot study of the microbiome in 238 samples taken from different locations along the entire female reproductive tract in hysterectomy patients with endometrial cancer (n=17), patients with endometrial hyperplasia (n=4) and patients afflicted with a benign uterine condition (n=10). Samples were collected aseptically both in the operating room and the pathology laboratory. Following DNA extraction, the 16S rDNA (V3-V5 region) microbial gene was amplified and sequenced to identify the microbiota present. The microbiome sequencing revealed a structural microbiome shift in the cancer and hyperplasia cases, distinguishable from the benign cases (p=0.01). Several taxa were found to be significantly enriched in samples belonging to the endometrial cancer cohort: Firmicutes (Anaerostipes, ph2, Dialister, Peptoniphilus, 1-68, Ruminococcus, and Anaerotruncus), Spirochaetes (Treponema), Actinobacteria (Atopobium), Bacteroidetes (Bacteroides and Porphyromonas), and Proteobacteria (Arthrospira). Of particular relevance, the simultaneous presence of Atopobium vaginae and an uncultured representative of the Porphyromonas sp. (99% match to P.somerae) were found to be predictive of the disease status (sensitivity 73-93%; specificity 67-90%, AUC 0.918). Sensitivity is increased to 100% if combined with a high vaginal pH (>4.5), although specificity is decreased to 60%. Although our numbers are low, the microbiome signature of hyperplasia was even more distinct from benign disease than endometrial cancer itself. This is suggestive of an early microbiome role in the disease. Given the pathogenic profile of the identified microorganisms these findings raise the possibility of a microbiome role in the etiology or progression of endometrial cancer that should be further investigated. Citation Format: Marina Walther-Antonio, Jun Chen, Francesco Multinu, Alexis Hokenstad, Tammy Distad, Heidi Cheek, Gary Keeney, Douglas Creedon, Heidi Nelson, Andrea Mariani, Nicholas Chia. Endometrial cancer microbiome signature and its implications for carcinogenesis. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr B45.
Authors' Response to Bozkurt et al.
Rivera, Marcelino , Krambeck, Amy E.

Mayo Clinic

Journal of Endourology | May 8, 2017 | Volume: 31 | Issue: 5 | Pages: 546-546

10.1089/end.2017.29028.riv | PMID 28481689 Get It